Ajanta Pharma launches generic ADHD treatment drug in US
New Delhi: Drug firm Ajanta Pharma said it has launched generic Clonidine Hydrochloride extended-release tablets in the American market after receiving the US health regulator's nod.
The company has launched the tablets in the strength of 0.1 mg in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc, Ajanta Pharma said in a BSE filing.
The product is a generic version of Concordia Pharmaceuticals Inc's Kapvay tablets, it added.
The tablets are a part of the growing portfolio of products that the company has developed for the US market, Ajanta Pharma said.
Clonidine Hydrochloride extended-release tablets are used for the treatment of attention deficit hyperactivity disorder (ADHD).
The company currently has 22 final approvals for its abbreviated new drug applications (ANDAs) from the United States Food and Drug Administration (USFDA). It also has two tentative approvals and 15 ANDAs under review with the regulator, Ajanta Pharma said.
Till date, the drug maker has launched 16 products in the US market.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd